UK based biotech company Redx said that its lead selective ROCK2 compound has been shown to have broad potential in the treatment of fibrosis as per new in vivo data.
13 Feb 2019
22 Jan 2019
Nash Pharmaceuticals, a subsidiary of Breathtec Biomedical, has announced that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM mouse model from SMC Laboratories.
03 Dec 2018
UK-based Redx Pharma said it expects to start first-in-man studies with RXC006 during 2020 as the first pre-clinical data of the drug candidate has suggested that the compound has great potential as a fibrosis treatment.
29 Nov 2018
Cyxone said that T20K, its investigational drug for the treatment of multiple sclerosis (MS), has succeeded in a preclinical program by yielding positive results in the toxicology studies.
14 Nov 2018
Scientists at The Wistar Institute and collaborators have engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models.
09 Oct 2018
Inovio Pharmaceuticals said that it has completed animal testing of DNA-encoded monoclonal antibodies targeting the immune checkpoint molecule CTLA-4.
22 Aug 2018
Scientists in the UK claim to have identified a crucial molecular player in a subtype of lung cancer that could pave way for a new approach towards treating the condition.
20 Aug 2018
Scientists in the UK believe that patients with sudden liver failure could benefit from a new treatment in the future that could cut down the need for transplants by preventing a process called senescence with certain anti-cancer therapy drugs.
07 Aug 2018
Oxford BioMedica has collaborated with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations for the development of a long-term therapy to treat patients with cystic fibrosis.
16 Apr 2018
Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs.